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Background: Mounting evidence suggests that miRNAs have major functions in tumor pathogenesis, and this
study aimed to identify the candidate miRNA and investigate its role in nasopharyngeal carcinoma (NPC).
Methods: MiRNA and mRNA expressions were screened by microarray assays. The cell proliferation, colony formation
and migration ability were measured by MTT, soft agar and wound healing assays, respectively. The tumor growth
suppression was evaluated by xenografting in nude mice. The plasma miR-223 levels in NPC patients were detected by
TaqMan analysis. Real-time quantitative PCR and Western blotting were used to confirm miR-223 and MAFB expression
levels. The targeting relationship between miR-223 and MAFB was verified using dual luciferase reporter assay.
Results: The miR-223 expression was decreased in CNE-1, CNE-2 cells as compared with NP69 cells, an immortalized
human nasopharyngeal epithelial cell line, and its level also reduced in NPC patients’ plasma as compared with healthy
controls. Exogenous expression of miR-223 in CNE-2 cells could inhibit cell proliferation both in vitro and in vivo.
Extrogenous miR-223 in CNE-2 cells would decrease the ability of colony formation and migration. MAFB, a transcription
factor of Maf family members, was identified as a target gene of miR-223. We found that migration and invasion abilities
were inhibited by MAFB silencing.
Conclusions: MiR-223 negatively regulates the growth and migration of NPC cells via reducing MAFB expression, and
this finding provides a novel insight into understanding miR-223 regulation mechanism in nasopharyngeal carcinoma
tumorigenesis.
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Nasopharyngeal carcinoma (NPC) is a common malignant
tumor in the people of southern China, particularly in
Guangdong population [1]. Radiotherapy is a commonly
used method to treat NPC and combined with chemother-
apy to promote the survival rate of the patients. However,
NPC cells can easily invade local tissue even metastasize
to remote organs, so such relapse and metastasis result in
poor prognosis for the patients [2]. Therefore it is very* Correspondence: taoliby@hotmail.com; shemin.lu@gmail.com
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discovering new therapeutic approaches.
MicroRNAs (miRNAs) are endogenous non-coding
RNAs with approachable 22 nucleotides in length and
play an important role in physiological and pathological
conditions through cleaving or transcript suppressing
target mRNAs [3]. Accumulating evidence demonstrates
that miRNAs are associated with cancer occurrence.
And determination of miRNA levels has been proposed
as a biomarker for diagnosis and prognosis of various
cancers [4, 5]. Here, we identified miR-223 as down-
regulated in undifferentiated nasopharyngeal carcinoma
cell line CNE-2, compared with immortalized nasopha-
ryngeal epithelial cell line NP69. MiR-223 was firstly re-
ported to be involved in the regulation of human
granulopoiesis [6, 7]. Then it was found to be a potentialcle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
Yang et al. BMC Cancer  (2015) 15:461 Page 2 of 12biomarker for recurrent ovarian cancer [8]. In Hela cells,
overexpression of MiR-223 suppresses cell proliferation by
targeting IGF-1R [9]. It seems contradictory that miR-223
can suppress tumor invasion and metastasis through tar-
geting Artemin [10], but may promote tumor by inhibiting
the expression of EPB41L3, a tumor suppressor in human
NPC [10]. These findings suggest that miR-223 is associ-
ated with migration and invasion of malignant tumor.
However, to our knowledge, the role of miR-223 in naso-
pharyngeal carcinogenesis remains undefined.
The present study was performed to find the potential
miRNAs in NPC, and verify the role of target miRNA in
invasion and metastasis of the cells. Our results illumin-
ate the role of miR-223 in NPC development and pro-
vide valuable information for clinical implications.
Materials and methods
Cell culture
Highly and poorly differentiated human NPC cell lines
named as CNE-1 and 2 were established and kindly pro-
vided by Prof. Yi Zeng from the Institute of Virology, China
Institute of Preventive Medical Science, China [11]. The im-
mortalized human nasopharyngeal epithelial cell line named
as NP69 was kindly provided by Prof. Kaitai Yao from
Southern Medical University, Guangzhou, China. CNE-1
and CNE-2 cells were cultured in the DMEM medium con-
taining 10 % fetal bovine serum (FBS), and NP69 cells were
cultured in Keratinocyte-SFM (serum-free medium). Both
mediums were contained 100 units/ml penicillin G and
100 μg/ml streptomycin (Invitrogen). The transfection was
conducted with Lipofectamine™2000 reagent (Invitrogen).
Microarray analysis
For microarray assay of miRNAs, double-stranded cDNAs
were synthesized with the 2 μg total RNA, and
biotin-tagged cRNAs were obtained by the use of the
MessageAmp™ II aRNA Amplification Kit (Ambion).
The biotin-tagged cRNAs were fragmented into mixed
strands in accordance with the Affymetrix’s protocols. TheTable 1 Genes and primers for RT-qPCR
Gene Primer name Se
U6 Reverse transcription C
Sense G
Anti sense G






Anti sense Cfragmented cRNAs were hybridized with TaqMan® Human
MicroRNA Array Set v3.0 containing 754 transcripts.
Hybridization was performed at 45 °C with rotation for
16 h (Affymetrix GeneChip Hybridization Oven 640). The
GeneChip arrays were washed and then stained (streptavi-
din-phycoerythrin) on an Affymetrix Fluidics Station 450
followed by scanning on a GeneChip Scanner 3000.
MiRNA transfection and real-time quantitative PCR
MiR-223 mimic (Cat# miR10004570), miR-223 negative
control (Cat# miR01201), miR-223 (Cat# miRQ0004570)
and U6 (Cat# MQP-0201) real-time PCR primers RNA
oligonucleotides were obtained from RiboBio (http://www.
ribobio.com Guangzhou, China). miRNAs were trans-
fected to CNE-2 cells by using Lipofectamine®2000, with a
final concentration at 50 nM. The expression of miR-223
was measured by real-time quantitative PCR (RT-qPCR)
by using One Step SYBR® PrimeScript® RT-PCR Kit II
(Takara) and following the manufacturer’s protocol on
ABI 7500 HT real-time PCR detection system as normal-
ized to the housekeeping gene U6. The information about
primer sequences is depicted in Table 1.
Cell proliferation analysis
CNE-2 cells with a number of 5 × 103/well were seeded
into 96-well plates, incubated for 12 h, and then trans-
fection was performed. At 24 h after transfection, each
well was treated with 10 μL MTT solution (10 mg/ml in
PBS) and incubated sequentially at 37 °C. After the incu-
bation for 4 h, 100 μL of DMSO was added to dissolve
the crystals. Then the absorbance of each well in culture
plate was measured at 570 nm and 630 nm after oscil-
lated for 10 min at room temperature.
Colony formation assay
Two experiments were employed for measuring colony
formation ability. For plate colony formation, at 24 h
after transfection, 600 cells were plated for 10 days. The
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diameter plates with 0.6 % base agar and 0.3 % top agar
and incubated 21 days. The colonies were count in 10
randomly chosen microscope fields.
Wound healing assay
The cells (2 × 105) were seeded into a 6-well plate. Then
the cells were scratched using a 100 μl tip when the cells
formed a confluent monolayer. The closure of scratch
was detected under the microscope at 0, 24, 48, 72 h
time point respectively after incubation.
Transwell migration and invasion assay
The ability of cells to migrate through filters was mea-
sured using Polycarbonate Membrane Transwell Inserts
(Corning). At 24 h after transfection, cells were trypsi-
nised. Cell culture inserts with a polycarbonate mem-
brane (8 μm pore size) were used. The bottom chamber
contained medium (0.5 ml) supplemented with 10 %
FBS, whereas the transfected cells were seeded into the
upper chamber and incubated for 36 h. The remaining
cells on the upper surface were mechanically removed.
Then the membranes were washed and stained using
0.1 % crystal violet. The cell migration ability was mea-
sured by the cell numbers that migrated to the lower
side of the filter. Experiments were repeated 3 times.
The invasion ability of cells was determined by a Matrigel
invasion chamber assay. This assay was conducted by the
use of 6.5 mm and 8 μm pore size Transwell chambers
(Corning). Cells transfected with miRNA mimic or control
one were cultured in serum-free medium for 12 h (1 × 105
cells per Transwell) and then the cells were migrated into
a medium containing 10 % FBS for 24 h. Cells that mi-
grated to the underside of the filter were fixed in methanol
and stained using 0.1 % crystal violet. Whole filters were
manually counted under the inverted microscope.
In vivo antitumor assay
Seven nude athymic mice (male, SPF grade, 6–8 weeks of
age) were purchased from Animal Experimental Center of
Guangdong Medical College. CNE-2 cells transfected with
miR-223 mimic and control microRNA (2 × 106) or MAFB
specific siRNA and negative control siRNA in 100 μl no
serum medium were injected respectively into particular
side of each mouse. Tumor size was measured every three
day and tumor volume was calculated as V = ab2/2, where
a is length and b is width of tumor. At day 23 after cell in-
jection, the animals were sacrificed and the tumors were
frozen quickly for following assays. Tissue sections were
fixed in 4 % paraformaldehyde and embedded in paraffin.
Three micrometer tissue sections were prepared and
stained with hematoxylin-eosin. All of the animal experi-
ments were approved by the Experimental Animal Care
and Use Committee in Guangdong Medical College.Patient plasma collection
Human plasma samples from NPC patients and healthy
donors were derived from the Affiliated Hospital of
Guangdong Medical College and Dongguan area in
China, with the informed consent under institutional re-
view board-approved protocols. Blood was collected in
EDTA tubes and processed for isolation of plasma within
2 h of collection. Blood was centrifuged at 2000 rpm at
room temperature for 10 min. Then the upper layer
plasma was transferred to RNase/DNase-free 1.5 ml con-
ical tubes and stored at −80 °C.
Total RNA was enriched from all plasma samples using
the TRIzol LS (Invitrogen). To normalize the different
RNA samples, 10 μl of synthetic cel-miR-39 (1.6 × 108
copies/μl) was added to each sample during the RNA iso-
lation. The reverse transcription was conducted using the
TaqMan miRNA Reverse Transcription Kit (Life Tech-
nologies), according to the manufacturer’s protocol. RT-
qPCR was carried out as described above. Data were
analyzed under the SDS Relative Quantification Software
version 1.4 (Applied BioSystems).Bioinformatics and dual luciferase reporter gene assay
Two widely advocated online bioinformatic softwares,
Target Scan [12] and microRNA.org [13], were used to
predict the interaction probability between miR-223 and
MAFB, including binding sites for miR-223 in MAFB
and the targeting efficiency. The predictive outcome was
used for further investigation.
A 249-bp-long MAFB 3’UTR fragment was cloned
into downstream region of the luciferase gene within the
pGL3 vector (Promega), namely the wild-type 3’UTR
(WT-UTR). The mutated MAFB 3’UTR containing
mutations of the miR-223 binding sit was obtained
using GeneTailor Site-Directed Mutagenesis System
(Invitrogen), namely mutated 3’UTR (mt-UTR). For
dual luciferase reporter assays, WT-UTR or mt-UTR
recombinant vector (0.5 μg per well) was cotransfected
with the normalizer vector pRL-CMV (0.5 μg per well
per well) coding for Renilla luciferase (Promega) using
Lipofectamin 2000™ (Invitrogen). The CNE-2 cells were
cultured in 24 wells plates with the density of 5 × 105
per well. Dual-Luciferase® Reporter 1000 Assay System
(Promega) was used to detect the luciferase activity at
36 h after transfection.cDNA microarray and confirmation
cDNA microarray analysis was performed on Human
Genome U133 Plus 2.0 gene chips by Capital Bio Cor-
poration (Beijing, China). The microarray results were
confirmed by RT-qPCR, with housekeeping gene GAPDH
as a normalizer.
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MAFB siRNA and negative control were synthesized by
RiboBio (Guangzhou, China). The transfection was per-
formed using Lipofectamin 2000™ (Invitrogen). Then the
cells were harvested 24 h after transfection, and the
MAFB expression level was measured by RT-qPCR as
described above.Western blotting
The total cell lysates were harvested and the total pro-
tein was separated on SDS-PAGE gel by Bio-rad system.
The anti-MAFB and anti-GAPDH antibodies were used
as the primary antibody (Abcam), with GAPDH as a
normalizer. The signal intensity was detected with the
enhanced chemiluminescence substrate kit (Thermo).Statistical analysis
Data were expressed as means ± standard deviation (SD),
and the the analysis between groups was performed by
Student’s t-test unless otherwise noted. Difference with a
P-value less than 0.05 was considered significant.Fig. 1 MiR-223 is down-regulated in human NPC cell lines and patients. a. Th
expressed miRNAs between CNE-1, CNE-2 and NP69 (changed more than 5 f
lower in CNE-1 and CNE-2 than that in NP69 (*P < 0.05). The miR-223 expressi
means ± SD from three independent experiments. c. The miR-223 expression
was normalized to cell-miR-39. The data were showed as means ± SD (n = 10Results
MiR-223 expression is significantly lower in CNE samples
than control samples
MiRNA expression profiling was conducted with a miRNA
microarray using RNAs isolated from human nasopha-
ryngeal carcinoma cell line CNE-1, CNE-2 and human
immortalized nasopharyngeal epithelial cell line NP69. A
total of 754 miRNAs were detected, in which 25 were in-
creased and 8 were decreased more than 5 folds in NPC
cells, compared with NP69 cells (Fig. 1a). MiR-223, which
was recently identified to be related with migration and
invasion of malignant tumors, was lower expressed in
NPC cell lines CNE-1 and CNE-2. We employed RT-
qPCR to validate the microarray results and a consistent
result was observed (P < 0.05; Fig. 1b). The expression
level of miR-223 was also down-regulated in another two
NPC cell lines HONE-1 and SUNE-1 (data no shown).
These results encouraged us to check the expression level
of miR-223 in clinical specimens. We found that the
average miR-223 level was significantly lower in the
plasma of 10 NPC patients than that from 10 normal
healthy subjects.e miRNA microarray analysis revealed that there were 33 differentially
olds). b. RT-qPCR confirmed that the miR-223 expression was significantly
on was analyzed with U6 as a normalizer. The data were showed as
was significantly decreased in NPC patients’ plasma. MiRNA abundance
)
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formation in vitro
In vitro, the cells transfected with miR-223 mimics
showed a higher miR-223 expression level (Fig. 2a). The
potential role of miR-223 mimic in cell proliferation and
colony formation was observed. As a result, the growth
rate was significantly decreased in CNE-2 cells due to
exogenous miR-223 (Fig. 2b). This observation suggested
that miR-223 may inhibit the proliferation of NPC cells.
This notion was further supported by the colony forma-
tion assay. As shown in Fig. 2c and d, both plate and soft
agar colony formation abilities were suppressed by ex-
ogenous miR-223 in CNE-2 cells.
MiR-223 inhibits NPC cell migration and invasion
The proliferation inhibition of miR-223 in CNE-2 cells
prompted us to examine the effect of miR-223 on the
migration and invasion of NPC cells. By wound healing
assay, we found that exogenous miR-223 inhibited CNE-
2 cell migration (Fig. 3a). Consistently, the results of
in vitro transwell migration and Matrigel invasion assay
showed that exogenous miR-223 inhibited CNE-2 cellsFig. 2 Exogenous miR-223 suppresses cell proliferation and colony formati
was significantly higher as compared with untreated and control group aft
viability was assayed one time a day from day 1 to day 7 after the transfec
c. After the transfection with miR-223 mimic or the negative control in CNE-2
was performed. The colony formation rate, clone number and total clone size
mimics or the negative control in CNE-2 cells and the 21 days incubation on
counted in 10 randomly chosen microscope fields and the colony formation
least three independent experiments. The data were showed as means ± SD.migration and invasion (Fig. 3b and c). These results
demonstrated that miR-223 inhibits the migration and
invasion of NPC cells in vitro.
MiR-223 suppresses tumor growth in vivo
As exogenous miR-223 suppresses cell proliferation of
NPC cells in vitro, we examined the effect of miR-223
in vivo. After injected with CNE-2 cells that were trans-
fected with miR-223 mimic or control microRNA re-
spectively, we found that tumors grew at a slower rate
and had smaller sizes (Fig. 4a-b). The total tumor size
for negative control and miR-223 mimic transfected
groups was 995.37 ± 674.63 and 598.38 ± 613.23 mm3
respectively (Fig. 4c). Morphological similarity of the xeno-
graft to the human NPC was evident on paraffin-embedded
sections stained with hematoxylin-eosin (Fig. 4d). These
results indicated that exogenous miR-223 suppresses
tumor growth in vivo.
MAFB is identified as a direct target of miR-223
The miR-223 expression level in CNE-1, CNE-2 and
NP69 cell lines was measured by RT-qPCR. Comparedon in vitro. a. RT-qPCR result confirmed that the miR-223 expression
er exogenous miR-223 transfection in CNE-2 (*P < 0.05). b. MTT cell
tion of either miR-223 mimic or the negative control in CNE-2 cells.
cells and the 10 days incubation on plates, the colony formation assay
were calculated respectively. d. After the transfection with miR-223
soft agar, the colony formation assay was performed. Colonies were
rate, clone number and total clone size was calculated. We performed at
* indicates P < 0.05 compared with control group
Fig. 3 Exogenous miR-223 suppresses cell migration and invasion in vitro. a. The function of exogenous miR-223 on CNE-2 cells migration. CNE-2
cells were cultured in 6-well plates. After the wound was made, images were captured at 0 h, 24 h, 48 h and 72 h time point respectively. b. The
effect of exogenous miR-223 on CNE-2 migration through Membrane Transwell assay. c. The effect of miR-223 on CNE-2 invasion by Matrigel
invasion assay. The experiments were conducted at least 3 times. The data were showed as means ± SD. * indicates P < 0.05 compared with
control group
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in NPC cell line CNE-1 and CNE-2 (Fig. 5a) that was
consistent with the miRNA microarray results (Fig. 1a).
The MAFB gene expression in CNE-1, CNE-2 and NP69
was also checked through RT-qPCR and Western blot-
ting. As shown in Fig. 5b, MAFB gene expression was
significantly higher in CNE-1, CNE-2 cells compared
with NP69. To investigate the mechanism of miR-223
inhibition NPC cells, we performed a cDNA expression
microarray analysis. After 24 h transfection of miR-223
mimic and negative control in CNE-2, total RNA was
isolated and hybridized to an Affymetrix GeneChip Hu-
man Genome U133 Plus 2.0 Array. We found that 39
transcripts were differentially expressed between two
groups (Fig. 5c). The microarray results for miR-223
down-regulated MAFB gene expression were verifiedthrough RT-qPCR and Western blotting. We obtained
the consistent result that miR-223 suppressed MAFB
gene expression in CNE-2 cells (Fig. 5d). Therefore, we
focused on MAFB and observed its role on CNE-2 cell
biology function. Combined bioinformatics results (Fig. 5e)
with the dual luciferase reporter assay (Fig. 5f), we identi-
fied MAFB as one of miR-223 target genes for further
investigation.
MAFB siRNA inhibits CNE-2 cells growth and migration
The inhibition activity for MAFB specific siRNA on
CNE-2 MAFB gene expression was confirmed by RT-
qPCR and Western blotting. MAFB specific siRNA
could attenuate CNE-2 cells MAFB gene expression for
28 % in mRNA level and 58 % in protein level respect-
ively (Fig. 6a and b). By wound healing assay, we found
Fig. 4 Exogenous miR-223 attenuates nasopharyngeal tumor growth in mouse xenograft models. a. The appearance of xenograft subcutaneous
NPC in miR-223 mimics transfection and control groups. b. Growth curves of subcutaneous NPC in nude mice with miR-223 mimics transfection
revealed that tumor growth significantly slowed down compared with control group. c. Total tumor weight of miR-223 mimic transfection and
control groups. d. HE staining result of the tumor formed in nude mice using, all of them were typical nasopharyngeal squamous cell carcinoma.
The data were showed as means ± SD (n = 7). * and ** indicate P < 0.05 and P < 0.01 as compared with control group
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migration (Fig. 6c). The inhibition activity of MAFB spe-
cific siRNA in CNE-2 cells proliferation and colony for-
mation was observed. Consistently, results from in vitro
transwell migration and Matrigel invasion assay showed
that MAFB specific siRNA inhibited CNE-2 cell migra-
tion and invasion (Fig. 6d and e). As a result, down-
regulation of MAFB could significantly decrease the
growth rate of CNE-2 cells (Fig. 6f ). These results indi-
cated that miR-223 inhibits the growth and migration of
NPC cells through reducing MAFB gene expression.
MAFB siRNA inhibits the growth of NPC xenograft tumors
CNE-2 cells were transfected respectively with MAFB
specific siRNA and negative control siRNA and then the
transfected cells were injected subcutaneously into the dif-
ferent dorsal flank of nude mice. Compared with the
negative control side, the tumors of MAFB siRNA side
grew more slowly, with the smaller size. In all 6 mice for
MAFB specific group, 4 mice could be seen tumors
growth after 23 days while there was tumor growth in all
negative control group (Fig. 7a). The total tumor weight
and size was 2236.80 ± 170.17 mg and 2428.79.80 ±
217.27 mm3 for negative control group and 729.80 ±
178.83 mg and 1029.41 ± 207.85 mm3 for MAFB specificsiRNA transfected group, respectively (Fig. 7b and c; * p <
0.05). Morphological similarity of the xenograft to the hu-
man NPC was evident on paraffin-embedded sections
stained with hematoxylin-eosin (Fig. 7D). These results in-
dicated that exogenous MAFB specific siRNA suppresses
tumor growth in vivo.
Discussion
To sum up, we report here that miR-223 plays a critical
role in NPC carcinogenesis. The plasma miR-223 level
was lower in NPC cells and NPC patients’ plasma, as
compared with normal ones. To fully realize its effect,
we observed that miR-223 inhibited NPC cell growth,
migration and invasion both in vitro and in vivo. MAFB
was identified as a miR-223 target gene. And MAFB ex-
pression was decreased accompanied with miR-223 over-
expression. In addition, the consistent result was observed
that the cell growth and migration were inhibited after
MAFB specific siRNA transfected into NPC cells. The
findings implicated that miR-223 could be a potential tar-
get for intervention and diagnosis to NPC.
NPC is a highly prevalent malignant cancer in south
China and Southeast countries. It has been known that
virus, diet and genetic makeups all are the risk factor for
NPC development, but underlying pathogenesis of the
Fig. 5 MAFB is a direct target gene of miR-223. a. The RT-qPCR confirmed that the miR-223 expression was significantly lower in CNE-1 and CNE-2
than that in NP69 (*P < 0.05). b. MAFB gene expression level in NP69 and NPC cell line CNE-1 and CNE-2 was measured by RT-qPCR and western blot.
c. The cDNA microarray analysis revealed that there were 39 differentially expressed genes between the CNE-2 transfected with miR-223 mimics and
the CNE-2 transfected with negative control. d. RT-qPCR confirmed that the gene expression of MAFB was inhibited by miR-223 overexpression. The
inhibition of MAFB gene expression on protein level through miR-223 mimic administration was confirmed by Western blotting. e. Schematic diagram
of MAFB 3’ UTR-containing reporter gene constructs. f. Dual luciferase reporter assay in CNE-2 co-transfected with WT-UTR or mt-UTR recombinant
vector (0.5 μg) and miR-223 (50 nM) as indicated. The experiment was performed at least 3 times. The data were showed as means ± SD. * indicates
P < 0.05 compared with control group
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tumor suppressing genes might form a very complicated
network, and how they interact one another to lead to
the cancer is not clear [15]. Few reports have indicated
that miRNAs abnormally express in different cancers,
and more researchers have been paying close attentions
to molecular mechanisms of miRNAs in tumorigenesis
[16]. In NPC, down-expressed miR-29c could upregulate
mRNA expression of extracellular matrix genes [17], and
ZEB2 and CTNNB1 low-expression induced by miR-
200a inhibits the growth, migration and invasion of NPC
cells [18]. In addition, miR-216b suppresses the prolifer-
ation and invasion via inhibiting KRAS expression [19].
Mir-218 exerts suppressing function to NPC by down-
regulating survivin expression and SLIT2-BOBO1 path-
way [20], and miR-26a acts the similar function forinhibiting cell growth and tumorigenesis through repres-
sion of EZH2miR [21]. Recent study reported that miR-663
targets p21 (WAF1/CIP1) to promote the proliferation
and development of NPC [22]. Those results have shed
light on which miRNAs are involved in NPC tumorigen-
esis, however, the role of miRNAs in pathogenesis has not
been elucidated.
Based on miRNA microarray we found that miR-223
was down-regulated in NPC cell line CNE-1 and CNE-2,
and further verified the role of miR-223 in NPC patho-
genesis. Using microarray-based serum miRNA profiling
and RT-qPCR method, Zeng et. al. compared serum
miRNAs level between the patients with nasopharyngeal
carcinoma and non-cancerous volunteers, and they
found that miR-223 was decreased significantly in the
serum of NPC patients [23]. Our results confirmed this
Fig. 6 Inhibition of MAFB gene expression suppresses cell migration, invasion and proliferation in vitro. a. RT-qPCR confirmed that the gene
expression of MAFB was inhibited by MAFB specific siRNA. b. Western blotting shown the inhibition of MAFB gene expression on protein level
through MAFB specific siRNA administration. c. The effect of MAFB-siRNA on CNE-2 migration. CNE-2 cells were cultured in 6-well plates. Images
were captured at 0 h, 24 h, 48 h and 72 h respectively, after the wound was made. d. Effect of MAFB specific siRNA on CNE-2 cells migration
through Membrane Transwell assay. e. Effect of MAFB specific siRNA on CNE-2 cell invasion by Matrigel invasion assay. f. MTT cell viability was
assayed once per day from day 1 to day 6 after the transfection of MAFB specific siRNA or the negative control in CNE-2 cells. The experiments
were performed at least 3 times. The data were showed as means ± SD. * indicates P < 0.05 compared with control group
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immortalized human nasopharyngeal epithelial cell line
NP69. Exogenously up-regulating miR-223 could suppress
cell proliferation and colony formation, increase tumor
formation in nude mice (Fig. 2 and 4). The results are
consistent with the discovery in hepatic carcinoma that
the inhibition of miR-223 accompanies the enhancement
of Stathmin1 expression [24]. In hematopoietic cells, miR-
223 can negatively post-transcript regulate the expression
of LMO2 and CEBP-β to reduce cell proliferation [25].
MiR-223 up-regulation in Hela cells inhibits cell prolifera-
tion by targeting IGF-1R [9]. However, in the gastric
cancer development, miR-223 acts as an oncogene to pro-
mote cell invasion and migration via affecting expressions
of EPB41L3 and FBXW7/hCdc4 genes [10, 26, 27]. In
addition, miR-223 has been report to regulate the prolifer-
ation and invasion of human breast cancer cells for target-
ing Caprin-1 [28]. On the other hand, there has been
another report suggesting that miR-223 functions as a po-
tent tumor suppressor of the Lewis lung carcinoma cellline by targeting insulin-like growth factor-1 [29]. Micro-
RNA 223 is up-regulated in the multistep progression
of Barrett’s esophagus and modulates sensitivity to
chemotherapy by targeting PARP1 [30], it also modu-
lates multidrug resistance via downregulation of ABCB1
in hepatocellular carcinoma cells [31]. In our study, we
demonstrated that exogenous miR-223 inhibits CNE-2 cell
migration and invasion (Fig. 3). The discrepant results of
miR-223 role seemed to indicate that miR-223 regulates
different gene expression to play different role in various
cancers.
In the normal cells, miRNAs maintain the homeostasis
of various life processes including proliferation, differen-
tiation and apoptosis. During the tumorigenesis, deregu-
lation of miRNAs can lead to various consequences
since various miRNAs bind with many mRNAs to regulate
gene expression [32]. Biological approaches are commonly
used to verify the relationship between miRNAs and
tumor phenotypes or to validate the possibility as a drug
target [33]. MiR-122 is significantly higher in the serum of
Fig. 7 Inhibition of MAFB gene expression attenuates nasopharyngeal tumor growth in mouse xenograft models. a. The appearance of xenograft
subcutaneous NPC in MAFB specific siRNA transfection and control groups. b. Total tumor weight of MAFB specific siRNA transfection and control
groups. c. Total tumor size of MAFB specific siRNA transfection and control groups. d. HE staining result of the tumor formed in nude mice using,
all of them were typical nasopharyngeal squamous cell carcinoma. The data were showed as means ± SD (n = 6). * indicate P < 0.05 as compared
with control group
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likely as a novel biomarker for screening the patients [34].
A plasma miRNA panel is discovered for early diagnosis
of hepatocarcinoma, and used in clinic to significantly re-
duce the frequency that optimal treatment window is
missing [34]. Osteosarcoma development is associated
with gene expression regulated by MiRNAs [4]. MiR-223/
Ect2/p21 signaling regulates osteosarcoma cell cycle pro-
gression and proliferation [35]. A study also reported that
miR-421 can be used as a biomarker to detect circulated
tumor cells of gastric cancer patients [5]. In addition,
many miRNAs have been discovered as a potential target
for diagnosis and treatment of human diseases. In the
serum from non-small lung cancer patients, miR-146b,
miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-
106a are significantly reduced but miR-29c increased [36].
The above-mentioned reports with our study indicate that
miR-223 could be a serum biomarker of NPC patients to
give early diagnosis for optimal treatment.MAFB, a member of Maf protein family, is a transcrip-
tion factor with basic-leucine zipper structure and plays
an important role in early tissue specification and ter-
minal differentiation [37]. In multiple myeloma, MAFB
can make hematopoietic stem/progenitor cells repro-
gramed into malignant plasma cells [38]. In addition,
MAFB is expected to be highly sensitive and very spe-
cific biomarker for poor prognosis of multiple myeloma
patients [39]. Further studies need to illustrate the role
of MAFB in NPC carcinogenesis.
Conclusion
In this study, we found the reduction of miR-223 expres-
sion both in NPC cells and in NPC patients’ plasma.
After miR-223 mimic and negative control microRNA
transfected, we found that 39 transcripts were differen-
tially expressed between two groups. Those transcripts
have not been reported as targets for miR-223. We also
used Target Scan and microRNA.org software to predict
Yang et al. BMC Cancer  (2015) 15:461 Page 11 of 12the potential targets for miR-223 and combined the results
to select MAFB for further investigation. MiR-223-mimic
administration could lead to the suppression of MAFB ex-
pression both in RNA and protein levels. In addition, both
of miR-223-mimic administration and reduction of MAFB
expression all lead to the inhibition of cell growth and
migration. These findings demonstrated that miR-223 reg-
ulates the NPC development by targeting MAFB expres-
sion, and implicates miR-223 as a candidate target for
NPC diagnosis and treatment. As miR-223 maybe also tar-
gets other genes in nasopharyngeal carcinoma, further
analyses are needed to elucidate the full spectrum of miR-
223 functions.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
WY conducted the whole experiment. DL provided necessary technical
guides. XL and SL edited the manuscript and were responsible for the paper
submission process. SL and TL were responsible for all the required funds
raising, experiment designing and paper appraisal as the study directors.
All authors read and approved the final manuscript.
Acknowledgements
The authors should express gratitude to Professor Yi Zeng from the Institute
of Virology, China Institute of Preventive Medical Science, for kindly
providing the human NPC CNE-2 cell line. This study was supported by the
Dongguan Higher Education Science and Technology Program
(2011105102016 and 2012105102005) and foundation for special talent
introduction of Guangdong province high education.
Author details
1Department of Biochemistry and Molecular Biology, School of Medical Basic
Sciences, Xi’an Jiaotong University Health Science Center, Xi’an, Shaanxi
710061, P. R. China. 2Dongguan Guanghua Hospital, Dongguan, Guangdong
523416, P. R. China. 3Guangdong Provincial Key Laboratory of Medical
Molecular Diagnostics, Guangdong Medical College, Dongguan, Guangdong
523808, P. R. China.
Received: 17 June 2014 Accepted: 21 May 2015
References
1. Jia WH, Luo XY, Feng BJ, Ruan HL, Bei JX, Liu WS, et al. Traditional
Cantonese diet and nasopharyngeal carcinoma risk: a large-scale case–
control study in Guangdong, China. BMC Cancer. 2010;10:446.
2. Razak AR, Siu LL, Liu FF, Ito E, O’Sullivan B, Chan K. Nasopharyngeal
carcinoma: the next challenges. Eur J Cancer. 2010;46(11):1967–78.
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell.
2004;116(2):281–97.
4. Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, et al. miRNA
Signatures Associate with Pathogenesis and Progression of Osteosarcoma.
Cancer Res. 2012;72(7):1865–77.
5. Zhou H, Xiao B, Zhou F, Deng H, Zhang X, Lou Y, et al. MiR-421 is a
functional marker of circulating tumor cells in gastric cancer patients.
Biomarkers. 2012;17(2):104–10.
6. Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C, et al. A
minicircuitry comprised of microRNA-223 and transcription factors NFI-A
and C/EBPalpha regulates human granulopoiesis. Cell. 2005;123(5):819–31.
7. Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, et al.
Regulation of progenitor cell proliferation and granulocyte function by
microRNA-223. Nature. 2008;451(7182):1125–9.
8. Laios A, O’Toole S, Flavin R, Martin C, Kelly L, Ring M, et al. Potential role of
miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer. 2008;7:35.
9. Jia CY, Li HH, Zhu XC, Dong YW, Fu D, Zhao QL, et al. MiR-223 suppresses
cell proliferation by targeting IGF-1R. PLoS One. 2011;6(11):e27008.10. Li T, Chen JX, Fu XP, Yang S, Zhang Z, Chen Kh H, et al. microRNA
expression profiling of nasopharyngeal carcinoma. Oncol Rep.
2011;25(5):1353–63.
11. Sizhong Z, Xiukung G, Yi Z. Cytogenetic studies on an epithelial cell line
derived from poorly differentiated nasopharyngeal carcinoma. Int J Cancer.
1983;31(5):587–90.
12. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by
adenosines, indicates that thousands of human genes are microRNA
targets. Cell. 2005;120(1):15–20.
13. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org
resource: targets and expression. Nucleic Acids Res. 2008;36:D149–153.
Database issue.
14. Yoshizaki T, Ito M, Murono S, Wakisaka N, Kondo S, Endo K. Current
understanding and management of nasopharyngeal carcinoma. Auris Nasus
Larynx. 2012;39(2):137–44.
15. Luo Z, Zhang L, Li Z, Li X, Li G, Yu H, et al. An in silico analysis of dynamic
changes in microRNA expression profiles in stepwise development of
nasopharyngeal carcinoma. BMC Med Genomics. 2012;5(1):3.
16. Wuchty S, Arjona D, Bozdag S, Bauer PO. Involvement of microRNA families
in cancer. Nucleic Acids Res. 2012;40(17):8219–26.
17. Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, Cheng YJ,
et al. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas,
up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad
Sci U S A. 2008;105(15):5874–8.
18. Xia H, Ng SS, Jiang S, Cheung WK, Sze J, Bian XW, et al. miR-200a-mediated
downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal
carcinoma cell growth, migration and invasion. Biochem Biophys Res
Commun. 2010;391(1):535–41.
19. Deng M, Tang H, Zhou Y, Zhou M, Xiong W, Zheng Y, et al. miR-216b
suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal
carcinoma. J Cell Sci. 2011;124(Pt 17):2997–3005.
20. Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, et al. MiR-218
suppresses nasopharyngeal cancer progression through downregulation of
survivin and the SLIT2-ROBO1 pathway. Cancer Res. 2011;71(6):2381–91.
21. Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, et al. MiR-26a inhibits cell
growth and tumorigenesis of nasopharyngeal carcinoma through repression
of EZH2. Cancer Res. 2011;71(1):225–33.
22. Yi C, Wang Q, Wang L, Huang Y, Li L, Liu L, Zhou X, Xie G, Kang T, Wang H
et al. MiR-663, a microRNA targeting p21(WAF1/CIP1), promotes the
proliferation and tumorigenesis of nasopharyngeal carcinoma. Oncogene.
2012;31(41):4421–33.
23. Zeng X, Xiang J, Wu M, Xiong W, Tang H, Deng M, et al. Circulating miR-17,
miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in
nasopharyngeal carcinoma. PLoS One. 2012;7(10):e46367.
24. Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF, et al. MicroRNA-223 is
commonly repressed in hepatocellular carcinoma and potentiates expression
of Stathmin1. Gastroenterology. 2008;135(1):257–69.
25. Sun W, Shen W, Yang S, Hu F, Li H, Zhu TH. miR-223 and miR-142
attenuate hematopoietic cell proliferation, and miR-223 positively
regulates miR-142 through LMO2 isoforms and CEBP-beta. Cell Res.
2010;20(10):1158–69.
26. Li J, Guo Y, Liang X, Sun M, Wang G, De W, Wu W: MicroRNA-223 functions
as an oncogene in human gastric cancer by targeting FBXW7/hCdc4. J Cancer
Res Clin Oncol. 2012;138(5):763–74.
27. Eto K, Iwatsuki M, Watanabe M, Ishimoto T, Ida S, Imamura Y, et al. The
sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/
FBXW7 pathway. Int J Cancer. 2015;136(7):1537–45.
28. Gong B, Hu H, Chen J, Cao S, Yu J, Xue J, et al. Caprin-1 is a novel
microRNA-223 target for regulating the proliferation and invasion of human
breast cancer cells. Biomed Pharmacother. 2013;67(7):629–36.
29. Nian W, Ao X, Wu Y, Huang Y, Shao J, Wang Y, et al. miR-223 functions as a
potent tumor suppressor of the Lewis lung carcinoma cell line by targeting
insulin-like growth factor-1 receptor and cyclin-dependent kinase 2. Oncol
Lett. 2013;6(2):359–66.
30. Streppel MM, Pai S, Campbell NR, Hu C, Yabuuchi S, Canto MI, et al.
MicroRNA 223 is upregulated in the multistep progression of Barrett’s
esophagus and modulates sensitivity to chemotherapy by targeting PARP1.
Clin Cancer Res. 2013;19(15):4067–78.
31. Yang T, Zheng ZM, Li XN, Li ZF, Wang Y, Geng YF, et al. MiR-223 modulates
multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma
cells. Exp Biol Med (Maywood). 2013;238(9):1024–32.
Yang et al. BMC Cancer  (2015) 15:461 Page 12 of 1232. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the
clinic: progress in validating and targeting microRNAs for cancer therapy.
Nat Rev Cancer. 2011;11(12):849–64.
33. Lujambio A, Lowe SW. The microcosmos of cancer. Nature.
2012;482(7385):347–55.
34. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, et al. Plasma microRNA panel to
diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol.
2011;29(36):4781–8.
35. Xu J, Yao Q, Hou Y, Xu M, Liu S, Yang L, et al. MiR-223/Ect2/p21 signaling
regulates osteosarcoma cell cycle progression and proliferation. Biomed
Pharmacother. 2013;67(5):381–6.
36. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC.
Circulating micro-RNA expression profiles in early stage nonsmall cell lung
cancer. Int J Cancer. 2012;130(6):1378–86.
37. Eychene A, Rocques N, Pouponnot C. A new MAFia in cancer. Nat Rev
Cancer. 2008;8(9):683–93.
38. Vicente-Duenas C, Gonzalez-Herrero I, Garcia Cenador MB, Garcia Criado FJ,
Sanchez-Garcia I. Loss of p53 exacerbates multiple myeloma phenotype by
facilitating the reprogramming of hematopoietic stem/progenitor cells to
malignant plasma cells by MafB. Cell Cycle. 2012;11(20):3896–900.
39. Stralen E, Leguit RJ, Begthel H, Michaux L, Buijs A, Lemmens H, et al. MafB
oncoprotein detected by immunohistochemistry as a highly sensitive and
specific marker for the prognostic unfavorable t(14;20) (q32;q12) in multiple
myeloma patients. Leukemia. 2009;23(4):801–3.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
